Pluri Inc./$PLUR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Ticker
$PLUR
Sector
Primary listing
Employees
135
Headquarters
Haifa, Israel
Website
Pluri Inc. Metrics
BasicAdvanced
$24m
-
-$2.83
0.75
-
Price and volume
Market cap
$24m
Beta
0.75
52-week high
$5.96
52-week low
$2.22
Average daily volume
15k
Financial strength
Current ratio
0.327
Quick ratio
0.294
Long term debt to equity
-43.08
Total debt to equity
-258.697
Interest coverage (TTM)
-27.97%
Profitability
EBITDA (TTM)
-25.515
Gross margin (TTM)
43.00%
Net profit margin (TTM)
-2,366.91%
Operating margin (TTM)
-2,410.84%
Effective tax rate (TTM)
0.11%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-51.24%
Return on equity (TTM)
430.57%
Valuation
Price to revenue (TTM)
18.971
Price to book
-1.27
Price to tangible book (TTM)
-0.97
Price to free cash flow (TTM)
-0.944
Free cash flow yield (TTM)
-105.96%
Free cash flow per share (TTM)
-2.405
Growth
Revenue change (TTM)
4.35%
Earnings per share change (TTM)
-21.54%
3-year revenue growth (CAGR)
83.02%
10-year revenue growth (CAGR)
-9.54%
3-year earnings per share growth (CAGR)
-26.84%
10-year earnings per share growth (CAGR)
-18.93%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs